
Novo Nordisk has confirmed that it has started a phase I trial of its SOMA robotic pill, currently known as DV3395.
This comes a week after MedWatch reported that the firm was starting trials involving an oral device. At the time, Novo Nordisk did not want to provide more details about the trial due to being in a quiet period in the run-up to the release of the quarterly report.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app